Novo Nordisk A/S (NYSE:NVO) Stock Holdings Trimmed by Highline Wealth Partners LLC

Highline Wealth Partners LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 75.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 583 shares of the company’s stock after selling 1,810 shares during the period. Highline Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $50,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in NVO. Novare Capital Management LLC raised its stake in Novo Nordisk A/S by 3.2% during the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after buying an additional 85 shares during the period. Steel Grove Capital Advisors LLC raised its holdings in Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock worth $541,000 after acquiring an additional 86 shares in the last quarter. Benjamin Edwards Inc. increased its position in shares of Novo Nordisk A/S by 2.6% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock worth $493,000 after purchasing an additional 87 shares during the last quarter. Rosenberg Matthew Hamilton raised its stake in shares of Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after purchasing an additional 94 shares in the last quarter. Finally, Burns J W & Co. Inc. NY boosted its holdings in shares of Novo Nordisk A/S by 1.9% in the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock valued at $647,000 after buying an additional 100 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVO. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $0.64 during trading on Friday, reaching $86.28. The company’s stock had a trading volume of 3,781,885 shares, compared to its average volume of 6,892,598. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12 month low of $81.50 and a 12 month high of $148.15. The firm has a 50 day moving average price of $100.86 and a 200 day moving average price of $119.79. The firm has a market capitalization of $387.18 billion, a price-to-earnings ratio of 27.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.